Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481819 | 1.00 | AGER (0.49) | AGERPPARAALBFFAR1FFAR4 | |
| SCHEMBL1481721 | 0.92 | PPARA (0.52) | PPARAALBFFAR1FFAR4CASP3 | |
| SCHEMBL1481717 | 0.92 | PPARA (0.52) | PPARAALBFFAR1FFAR4CASP3 | |
| SCHEMBL1481604 | 0.91 | CASP3 (0.50) | AGERPPARAALBFFAR1FFAR4 | |
| SCHEMBL1481600 | 0.91 | CASP3 (0.50) | AGERPPARAALBFFAR1FFAR4 | |
| SCHEMBL1481459 | 0.91 | PTGS2 (0.47) | AGERPPARAPTGS2PTGES | |
| SCHEMBL1481454 | 0.91 | PTGS2 (0.47) | AGERPPARAPTGS2PTGES | |
| SCHEMBL12754209 | 0.91 | RARB (0.47) | PPARAALBFFAR1CASP3SENP8 | |
| SCHEMBL1481325 | 0.90 | MMP2 (0.50) | AGERPPARAALBFFAR1CASP3 | |
| SCHEMBL1481323 | 0.90 | MMP2 (0.50) | AGERPPARAALBFFAR1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | AGER 1249/4885PPARA 2236/4885ALB 1690/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | AGER 1249/4885PPARA 2236/4885ALB 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.